Trial · NCT03711162
Results by group161
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 161
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual Rate of Decline in FVC up to Week 52 | GLPG1690 600 mg | -124.6 | Standard Error 27.15 | mL/year | |
| Annual Rate of Decline in FVC up to Week 52 | GLPG1690 200 mg | -173.9 | Standard Error 26.31 | mL/year | |
| Annual Rate of Decline in FVC up to Week 52 | Placebo | -147.3 | Standard Error 26.72 | mL/year | |
| Percentage of Participants With Disease Progression up to Week 52 | GLPG1690 600 mg | 17.8 | Percentage of participants | ||
| Percentage of Participants With Disease Progression up to Week 52 | GLPG1690 200 mg | 18.7 | Percentage of participants | ||
| Percentage of Participants With Disease Progression up to Week 52 | Placebo | 18.3 | Percentage of participants | ||
| Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | GLPG1690 600 mg | 9.5 | Percentage of participants | ||
| Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | GLPG1690 200 mg | 9.4 | Percentage of participants | ||
| Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | Placebo | 9.8 | Percentage of participants | ||
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | GLPG1690 600 mg | 3.3 | Standard Error 1.41 | Score on a scale | |
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | GLPG1690 200 mg | 4.1 | Standard Error 1.32 | Score on a scale | |
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | Placebo | 3.8 | Standard Error 1.36 | Score on a scale | |
| Annual Rate of Decline in FVC Until EoS | GLPG1690 600 mg | -127.0 | Standard Error 24.01 | mL/year | |
| Annual Rate of Decline in FVC Until EoS | GLPG1690 200 mg | -175.5 | Standard Error 22.97 | mL/year | |
| Annual Rate of Decline in FVC Until EoS | Placebo | -146.4 | Standard Error 23.59 | mL/year | |
| Percentage of Participants With Disease Progression Until EoS | GLPG1690 600 mg | 23.1 | Percentage of participants | ||
| Percentage of Participants With Disease Progression Until EoS | GLPG1690 200 mg | 24.6 | Percentage of participants | ||
| Percentage of Participants With Disease Progression Until EoS | Placebo | 21.3 | Percentage of participants | ||
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 100 | GLPG1690 600 mg | 11.4 | 95% Confidence Interval 0.3 to 22.6 | Score on a scale | |
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 100 | GLPG1690 200 mg | 10.5 | 95% Confidence Interval 1.1 to 20.0 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03711162/results